Showing results (21-30 of 497) with videos related to
Sort By:
Pageof 50
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder CancerChristopher M Russell, Amir H Lebastchi, Tudor Borza, et al.Current Osteoporosis Reports|June 20, 2018
Surgical Approach to Bone MetastasesGeoffrey W Siegel, J Sybil Biermann, Anda-Alexandra Calinescu, et al.International Journal of Radiation Oncology, Biology, Physics|June 13, 2018
Mentorship Experiences of Early-Career Academic Radiation Oncologists in North AmericaNafisha Lalani, Kent A Griffith, Rochelle D Jones, et al.European Urology|January 5, 2013
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortalityDaniel E Spratt, Chi Zhang, Zachary S Zumsteg, et al.International Journal of Radiation Oncology, Biology, Physics|July 17, 2012
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancerDaniel E Spratt, Xin Pei, Josh Yamada, et al.Clinical Nuclear Medicine|March 23, 2010
Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancerDaniel E Spratt, Roberto Diaz, James McElmurray, et al.Statistics in Medicine|April 12, 2021
Evaluation of predictive model performance of an existing model in the presence of missing dataPin Li, Jeremy M G Taylor, Daniel E Spratt, et al.Clinical Nuclear Medicine|December 10, 2015
ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical SourcesDaniel E Spratt, Bassem I Zaki, Benjamin L Franc, et al.Current Opinion in Urology|October 5, 2019
Tissue-based genomics: which test and whenRandy A Vince, Jeffrey J Tosoian, William C Jackson, et al.BMJ Case Reports|April 7, 2016
Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvementJonathan Bevan, Michael RichardsonPageof 50